Treatment of cryptococcosis in the setting of HIV coinfection

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 1019-1030

  Khawcharoenporn, Thana ^a,b   Apisarnthanarak, Anucha ^b   Mundy, Linda M ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Cryptococcosis; HIV; Infection; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CREATININE; ELECTROLYTE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; ITRACONAZOLE; MICAFUNGIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POSACONAZOLE; RECOMBINANT GAMMA INTERFERON; STEROID; VORICONAZOLE;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SOLUBILITY; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL PRESSURE; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUMBAR PUNCTURE; MONOTHERAPY; NAUSEA; PANCYTOPENIA; PANDEMIC; PATIENT MONITORING; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; CRYPTOCOCCOSIS; HIV; HIV INFECTIONS; HUMANS;

EID: 37349001292     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.1019     Document Type: Review

References (90)

1. Mirza SA, Phelan M, Rimland D et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. 36, 789-794 (2003).
2. Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis. 179, 449-454 (1999).
3. Chen S, Sorrell T, Nimmo G et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31, 499-508 (2000).
4. Brandt ME, Hutwagner LC, Klug LA et al. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J. Clin. Microbiol. 34, 912-917 (1996).
5. Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J. Med. Microbiol. 53, 935-940 (2004).
6. Tintelnot K, Lemmer K, Losert H, Schär G, Polak A. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses 47, 455-464 (2004).
7. Lizarazo J, Linares M, de Bedout C, Restrepo A, Agudelo CI, Castañeda E. Results of nine years of the clinical and epidemiological survey on cryptococcosis in Colombia, 1997-2005. Biomedica 27, 94-109 (2007).
8. Poonwan N, Mikami Y, Poosuwan S et al. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Eur. J. Epidemiol. 13, 335-340 (1997).
9. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection 35, 51-58 (2007).
10. Lortholary O, Poizat G, Zeller V et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20, 2183-2191 (2006).
11. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43, 1069-1073 (2006).
12. Morgan J, McCarthy KM, Gould S et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43, 1077-1080 (2006).
13. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr. HIV Res. 5, 355-360 (2007).
14. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; the French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 4, e21 (2007).
15. Witt MD, Lewis RJ, Larsen RA et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. Dis. 22, 322-328 (1996).
16. Fan-Havard P, Yamaguchi E, Smith SM, Eng RH. Diastolic hypertension in AIDS patients with cryptococcal meningitis. Am. J. Med. 93, 347-348 (1992).
17. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect. Dis. Clin. North Am. 20, 507-544 (2006).
18. Powderly WG. Current approach to the acute management of cryptococcal infections. J. Infect. 41, 18-22 (2000).
19. Brouwer AE, Rajanuwong, A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363, 1764-1767 (2004).
20. Micol R, Lortholary O, Sar B et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J. Acquir. Immune Defic. Syndr. 45, 555-559 (2007).
21. Liechty CA, Solberg P, Were W et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop. Med. Int. Health 12, 929-935 (2007).
22. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 710-718 (2000).
23. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337, 15-21 (1997).
24. Apisarnthanarak A, Powderly WG. Treatment of acute cryptococcal disease. Expert Opin. Pharmacother. 2, 1259-1268 (2001).
25. Hiemenz, JR, Walsh, TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22, S133 (1996).
26. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27, 603 (1998).
27. Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22, 315-321 (1996).
28. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11, 1463-1471 (1997).
29. Menichetti F, Florio M, Tosti A et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22, 838-840 (1996).
30. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/ day or 400 mg/day of fluconazole. BMC Infect. Dis. 6, 118 (2006).
31. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 113, 183-187 (1990).
32. Larsen RA, Bozzette SA, Jones BE et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19, 741-745 (1994).
33. Mayanja-Kizza H, Oishi K, Mitarai S et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26, 1362-1366 (1998).
34. Sobel JD. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin. Infect. Dis. 39, S224-S227 (2004).
35. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39, 598-601 (1995).
36. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36, 1221-1228 (2003).
37. de Gans J. Portegies P, Tiessens G et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 6, 185-190 (1992).
38. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J. Med. Assoc. Thai. 86, 293-298 (2003).
39. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149, 2301-2308 (1989).
40. Bozzette SA, Larsen RA, Chiu J et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Ingl. J. Med. 324, 580-584 (1991).
41. Powderly WG, Saag MS, Cloud GA et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J.Med. 326, 793-798 (1992).
42. Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 28, 291-296 (1999).
43. Vibhagool A, Sungkanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin. Infect. Dis. 36, 1329-1331 (2003).
44. Mussini C, Pezzotti P, Miró JM et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. 38, 565-571 (2004).
45. Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30, 47-54 (2000).
46. Woodworth GE, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg. Neurol. 63, 529-531 (2005).
47. Newton PN, Thai le H, Tip NQ et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis. 35, 769-772 (2002).
48. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 18, 789-792 (1994).
49. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45, 2862-2864 (2001).
50. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40, 1910-1913 (1996).
51. Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56, 745-755 (2005).
52. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on Cryptococcus neoformans. Antimicrob. Agents Chemother. 48, 2014-2020 (2004).
53. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36, 1122-1131 (2003).
54. Morrison VA. Echinocandin antifungals: review and update. Expett Rev. Anti Infect. Ther. 4, 325-342 (2006).
55. Pappas PG, Bustamante B, Ticona E et al. Recombinant interferon-γ 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189, 2185-2191 (2004).
56. Robinson PA, Bauer M, Leal MA et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28, 82-92 (1999).
57. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. 36, 690-692 (1992).
58. Coker RJ. Cryptococcal infection in AIDS. Int. J. STD AIDS 3, 168-172 (1992).
59. Khawcharoenporn T, Apisarnthanarak A, Kiratisin P, Mundy LM, Bailey TC. Evaluation of Cryptococcus laurentii meningitis in a patient with HIV infection: a case report and review of the literature. Hawaii Med. J. 65, 260-263 (2006).
60. Dannaoui E, Abdul M, Arpin M et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50, 2464-2470 (2006).
61. Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans. Drug Resist. Updat. 2, 259-269 (1999).
62. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43, 2163-2167 (2005).
63. Bii CC, Makimura K, Abe S et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Myroses 50, 25-30 (2007).
64. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin. Infect. Dis. 27, 260-264 (1998).
65. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J. Antimicrob. Chemother. 52, 683-686 (2003).
66. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J. Antimicrob. Chemother. 54, 563-565 (2004).
67. Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 49, 512-517 (2005).
68. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J. Antimicrob. Chemother. 56, 1144-1147 (2005).
69. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50, 2009-2015 (2006).
70. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50, 917-921 (2006).
71. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48, 201-205 (2004).
72. Shelburne SA, Darcourt J, White AC et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 40, 1049-1052 (2005).
73. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F; French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19, 1043-1049 (2005).
74. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81, 213-227 (2002).
75. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J. Infect. 51, e289-e297 (2005).
76. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin. Infect. Dis. 35, e128-e133 (2002).
77. Blanche P, Gombert B, Ginsburg C et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand. J. Infect. Dis. 30, 615-616 (1998).
78. Masur H, Kaplan JE, Holmes KK; US Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med. 137, 435-478 (2002).
79. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst. Rev. 3, CD004773 (2005).
80. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med. 5, 140-143 (2004).
81. Larsen RA, Pappas PG, Perfect J et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49, 952-958 (2005).
82. Casadevall A, Pirofski LA. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med. Mycol. 43, 667-680 (2005).
83. Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7, 829-835 (1993).
84. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 326, 83-89 (1992).
85. Physician Desk Reference. Product listings. In: RED BOOK: Pharmacy's Fundamental Reference. Thomson PDR, NJ, USA 211-245, 416, 480 (2006).
86. Physician Desk Reference. Product information: antifungals. In: PDR Concise Prescribing Guide. Thomson PDR, NJ, USA 53-55 (2007).
87. Havlir DV, Dubé MP, McCutchan JA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin. Infect. Dis. 27, 1369-1375 (1998).
88. Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J. Med. 332, 700-705 (1995).
89. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. Dis. 34, 277-284 (2002).
90. McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 28, 1049-1056 (1999).